Genix Receives Approval to Extend Warrants from the TSX Venture Exchange

Vancouver, British Columbia, July 28, 2022 – Genix Pharmaceuticals Corporation (TSX-V: GENX; OTCQB: GENPF) (“GENIX” or the “Company”) announces that the Company has received approval from the TSX Venture Exchange (the “Exchange”) to extend 3,354,945 previously issued and outstanding warrants (the “Warrants”) by eighteen (18) months (see July 20, 2022 press release).


In addition, Genix would like to provide a correction to the expiry date on 1,218,333 warrants as published July 20, 2022.  The warrants that are set to expire August 13, 2022 and will be extended 18 months to February 13, 2024 not February 13, 2023 as was written in the press release.


About Genix

Genix Pharmaceuticals Corporation is a novel and generic ophthalmic drugs company.  The Company is focused on the research, development, manufacture, licencing and sales of novel and innovative healthcare products. In particular, these products include evidence-based, proprietary over-the-counter (“OTC”) nutraceuticals, and other single molecule generic drugs that have been shown to deliver consistent and verifiable results in various therapeutic areas.

The Company will market and sell its portfolio of novel and generic ophthalmic drugs in Canada and globally and its nutraceutical products in North America and other select countries. Genix continues to conduct its scientific R&D of new, innovative products to support the health needs of mainstream consumers.


On Behalf of the Board of Directors,

Mr. Mahmoud Aziz, President, Director
Genix Pharmaceuticals Corporation


For more information regarding Genix Pharmaceuticals Corporation, please contact:

Kevin Bottomley, Director
Tel: +1.604.609.6199


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as, “forward‐looking statements”.  Forward‐looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions.  The Company cautions readers that forward‐looking statements, including without limitation those relating to the Company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward‐looking statements.



Previous Post
Genix Proposes to Extend Warrants
Next Post
Genix Announces Auditor Resignation

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.
You need to agree with the terms to proceed